Key Highlights

  • Hims & Hers Health shares are trading up 5.97% today, building on last week's rebound.
  • The rally comes ahead of the company's second-quarter earnings report, due after market close on August 10.
  • Analysts expect revenue of approximately $692 million and an EPS loss of $0.07 for the quarter.
  • The move coincides with a broader rotation into healthcare stocks and continued platform expansion.

What's Happening With Hims & Hers Stock Today?

Hims & Hers Health (NYSE:HIMS) shares are climbing further today as investors position ahead of the company's second-quarter earnings report, due after market close on August 10. The move builds on last week's rebound from a selloff tied to a Federal Trade Commission-related issue. Analysts currently expect revenue of approximately $692 million and an adjusted EPS loss of $0.07 for the quarter, with full-year 2026 revenue guidance previously raised to a range of $2.8 billion to $3 billion.

Hims & Hers Health is a multi-specialty telehealth platform founded in 2017 and headquartered in San Francisco, California, connecting consumers with licensed healthcare professionals for virtual consultations and ongoing care, delivering prescription medications alongside a broad range of over-the-counter products through its websites and mobile app.

Sector Rotation and Product Expansion

Today's gain also coincides with a broader rotation into healthcare stocks this week, with sector funds showing renewed interest across telehealth and consumer health names. Hims & Hers continues expanding its platform through recent product launches, including a new AI-native Hers app and smart scale for weight-loss members, aimed at deepening the company's consumer ecosystem ahead of the print.

Investors are also weighing intensifying GLP-1 competition, with the company navigating its pivot away from compounded GLP-1 products while facing branded drug competition from Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY), even as international revenue surged 969% year-over-year in the first quarter.

Conclusion

Hims & Hers Health shares are rising today as investors position ahead of next week's second-quarter earnings report, building on last week's rebound and continued platform expansion. With options markets implying a modest post-earnings move, the print will be closely watched for signs of how the company's pivot away from compounded GLP-1 products is progressing.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.